TLSITriSalus Life Sciences Inc
TLSI
TriSalus Life Sciences Inc299
Mkt Cap
$258.71MVolume
146,052.0052W High
$7.9552W Low
$3.42PE Ratio
-2.31TLSI Fundamentals
Price
$4.22Prev Close
$4.23Open
$4.2050D MA
$4.50Beta
0.55Avg. Volume
225,571.25EPS (Annual)
-$1.84P/B
-6.23Rev/Employee
$442,656.86$278.53
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·2d ago
TriSalus Life Sciences Names Richard Marshall As Chief Medical Officer
(RTTNews) - TriSalus Life Sciences, Inc. (TLSI) on Tuesday said it has appointed Richard Marshall as chief medical officer, effective June 29, 2026...
Nasdaq News: Markets·4d ago
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·4d ago
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells 4,358 Shares of Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the business's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $4.13, for a total value of $17,998.54. Following the transaction, the chief executive...
MarketBeat·21d ago
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the firm's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $4.13, for a total value of $17,998.54. Following the transaction, the chief executive officer...
MarketBeat·22d ago
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 15,944 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.85, for a total value of $61,384.40. Following the sale, the chief executive officer owned 752,987...
MarketBeat·22d ago
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·24d ago
Research Analysts Issue Forecasts for TLSI Q1 Earnings
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Analysts at Northland Securities issued their Q1 2026 earnings per share estimates for TriSalus Life Sciences in a research report issued on...
MarketBeat·1mo ago
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·1mo ago
Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price
Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a "buy" rating for the company in a report on Friday...
MarketBeat·1mo ago
<
1
2
...
>